Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2024; 14(6): 135-146


Toxicity and biodistribution of alginate-stabilized AgNPs upon 14-days repeated dose oral administration in mice

Dian Pribadi Perkasa, Wawaimuli Arozal, Kusmardi Kusmardi, Mukh Syaifudin, Tri Purwanti, Roza Indra Laksmana, Afiq Azfar Pratama, Irawan Sugoro, Dien Puji Rahayu.




Abstract

This study evaluated the effect of incremental doses of oral alginate-stabilized silver nanoparticles (AgNPs) on toxicity outcomes and biodistribution over 14 days. Twenty-five male ddY mice strain were randomly divided into five groups as follows: control, silver ion 5.0 mg/kg BW, and AgNPs 2.5, 5.0, and 10.0 mg/kg BW, respectively. There were no significant effects on body weight, organ index, hematology, or biochemical parameters in AgNP-treated mice at doses of up to 10 mg/kg BW. The silver content in tissue was undetectable, and no toxic effect was observed upon repeated oral administration at 2.5 mg/kg BW. However, histopathological analysis showed mild to severe colon and liver injuries in AgNPs groups at doses 5.0 mg/kg BW and higher. While, silver ion seems the most toxic form of silver which showed the highest silver deposition in all studied organs, an increase in Alt and lactate dehydrogenase levels, and perform severe pathological features in liver and colon tissues. These results suggest that the liver is the main target organ for toxicity of alginate-stabilized AgNPs. In the context of locally acting drugs, further bioactivity study on alginate-stabilized AgNPs is recommended at a dose lower than 2.5 mg/kg BW in which inconspicuous toxic effect is observed upon repeated oral administration.

Key words: silver nanoparticles; alginate; toxicity; biodistribution; systemic uptake






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.